In this week's episode: Pfizer’s backroom US pricing deal; confusion over Japan’s pharma tariffs; more direct-to-patient schemes in the US; first approval for Novartis’s remibrutinib; and GSK’s CEO to step down.

test carousel-test

test carousel-Medtech

test carousel-In-Vivo

test carousel-HBW